Apollohosp FY24 Annual Earnings Summary

Overall occupancy at 62% remains below the 70% target, with new hospitals at 60% and some regions like Tamil Nadu seeing muted volumes due to seasonal factors.

Combined pharmacy EBITDA margins are under pressure due to 20% of stores yet to reach breakeven, and new hospitals face margin drag from doctor hiring and marketing costs.

The decision to reduce discounts and filter low-value orders led to a sequential decline in pharmacy GMV, and achieving the INR 3,000 crore GMV target may be challenging.

Inpatient volume growth was muted in core southern markets due to a delayed monsoon, reducing seasonal medical admissions.

Analyst raised concern that new bed additions (Pune, Kolkata, Hyderabad) could drag margins until they reach breakeven in 12-18 months.

Analyst questioned whether expansion in metros (where supply is strong) is prudent versus non-metros where Apollo has an early-mover advantage.

New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.

Despite adding 2 million new users, daily active users declined sequentially, raising concerns about user engagement and monetization.

Four new hospitals with 1,500 beds to be operationalized by calendar 2025-26; initial costs could pressure margins.

150 new doctors hired in FY24; full revenue contribution expected only by Q2 FY25, posing near-term margin risk.

Management deferred providing an update on the lease renewal for Indraprastha Medical, which could impact future operations and expansion plans.

Q3 saw lower elective surgeries due to holidays and Chennai cyclone, affecting revenue mix and margins. Similar events could recur.